GenMark Diagnostics Gross Profit

The latest gross profit for GNMK is $68M as of December 2020. That compares with $29M in the prior-year period — up 137.5% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside GenMark Diagnostics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GNMK's gross profit moved from $29M to $68M — a 137.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GenMark Diagnostics's operating scale or balance-sheet position.

Against Healthcare companies, GNMK currently prints $68M for gross profit, while the sector average sits near $65B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at GenMark Diagnostics's growth, margins, and balance sheet.

A gross profit figure of $68M for GNMK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting GNMK's gross profit ($68M), review year-over-year change from $29M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.